Janus Henderson Group
ARCT icon

Janus Henderson Group’s Arcturus Therapeutics ARCT Stock Holding History

Janus Henderson Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,972
Closed -$231K – 2527
2024
Q3 		$231K Hold
9,972
– – ﹤0.01% 2378
2024
Q2 		$242K Sell
9,972
-126
-1% -$3.82K ﹤0.01% 2313
2024
Q1 		$340K Buy
10,098
+1
+0% +$35 ﹤0.01% 2179
2023
Q4 		$318K Sell
10,097
-19
-0.2% -$452 ﹤0.01% 2211
2023
Q3 		$258K Buy
10,116
+9
+0.1% +$277 ﹤0.01% 2262
2023
Q2 		$290K Sell
10,107
-13
-0.1% -$354 ﹤0.01% 2263
2023
Q1 		$242K Buy
+10,120
New +$182K ﹤0.01% 2388
2020
Q4 		– Sell
-483,078
Closed -$20.7M – 1385
2020
Q3 		$20.7M Buy
483,078
+337,270
+231% +$16.7M 0.01% 700
2020
Q2 		$6.81M Buy
+145,808
New +$5.03M ﹤0.01% 877

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group's ARCT Position: Q4 2024 in Review

Janus Henderson Group sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 9,972 shares — an estimated $231K sold.

Janus Henderson Group first reported a position in ARCT in Q2 2020 and held it in 9 quarters. The position peaked at $20.7M in Q3 2020. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Janus Henderson Group reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Janus Henderson Group sold 9,972 Arcturus Therapeutics shares in Q4 2024, an estimated $231K.
  • Janus Henderson Group first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 9 quarters.
  • Janus Henderson Group's Arcturus Therapeutics position peaked at $20.7M in Q3 2020.
  • 147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Janus Henderson Group's 13F filing for Q4 2024, filed 14 Feb 2025.